Treating BCRL with ADRCs and Lipotransfer

Results from a long‐term, open‐label, phase I study from the laboratory of Mads Gustaf Jørgensen (Odense University Hospital, Denmark) provide evidence that adipose‐derived regenerative cells (ADRCs) and lipotransfer represent a safe and feasible intervention in patients with breast cancer‐related lymphedema (BCRL). As reported in their recent STEM CELLS Translational Medicine article, the authors show that the effectiveness observed shortly after treatment extended to up to four years after treatment; however, they also note that these promising results will require evaluations in a randomized, controlled, and blinded study to further document clinical efficacy.